p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials.
Lehmann-Che J, André F, Desmedt C, Giacchetti S, Sotiriou C, Turpin E, Espié M, Marty M, Piccart M, Pusztai L, De Thé H. p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials. Cancer Research 2009, 69: 6064. DOI: 10.1158/0008-5472.sabcs-6064.Peer-Reviewed Original ResearchPathologic complete responseAnthracycline-based chemotherapyPCR rateWild-type tumorsP53 wild-type tumorsP53 mutationsType tumorsPredictive valueAnthracycline-containing chemotherapyBreast cancer patientsDifferent clinical trialsDifferent clinical studiesP53 mutant tumorsInvasive tumor cellsDose intensityComplete responseLymph nodesCancer patientsNegative cancersClinical trialsBreast cancerClinical studiesEstrogen receptorTOP trialPatients